1	A	DT	3	det
2	new	JJ	3	amod
3	drug	NN	14	nsubjpass
4	to	TO	5	aux
5	prevent	VB	3	infmod
6	the	DT	7	det
7	rejection	NN	5	dobj
8	of	IN	7	prep
9	transplanted	JJ	10	amod
10	organs	NNS	8	pobj
11	has	VBZ	14	aux
12	been	VBN	14	auxpass
13	successfully	RB	14	advmod
14	used	VBN	0	root
15	on	IN	14	prep
16	more	JJR	17	mwe
17	than	IN	18	quantmod
18	100	CD	19	num
19	patients	NNS	15	pobj
20	at	IN	14	prep
21	the	DT	22	det
22	University	NNP	20	pobj
23	of	IN	22	prep
24	Pittsburgh	NNP	23	pobj
25	,	,	14	punct
26	according	VBG	14	prep
27	to	TO	26	pcomp
28	researchers	NNS	27	pobj
29	.	.	14	punct

1	The	DT	2	det
2	drug	NN	15	nsubjpass
3	,	,	2	punct
4	which	WDT	5	nsubj
5	is	VBZ	2	rcmod
6	still	RB	5	advmod
7	in	IN	5	prep
8	the	DT	10	det
9	experimental	JJ	10	amod
10	phase	NN	7	pobj
11	,	,	2	punct
12	has	VBZ	15	aux
13	n't	RB	15	neg
14	been	VBN	15	auxpass
15	approved	VBN	0	root
16	yet	RB	15	advmod
17	by	IN	15	prep
18	the	DT	22	det
19	Food	NNP	22	nn
20	and	CC	19	cc
21	Drug	NNP	19	conj
22	Admistration	NNP	17	pobj
23	,	,	15	punct
24	and	CC	15	cc
25	its	PRP$	27	poss
26	long-term	JJ	27	amod
27	effects	NNS	29	nsubj
28	are	VBP	29	cop
29	unknown	JJ	15	conj
30	.	.	15	punct

1	But	CC	3	cc
2	researchers	NNS	3	nsubj
3	say	VBP	0	root
4	the	DT	5	det
5	drug	NN	11	nsubj
6	,	,	5	punct
7	called	VBN	5	partmod
8	FK-506	NNP	7	dep
9	,	,	5	punct
10	could	MD	11	aux
11	revolutionize	VB	3	ccomp
12	the	DT	14	det
13	transplantation	NN	14	nn
14	field	NN	11	dobj
15	by	IN	11	prep
16	reducing	VBG	15	pcomp
17	harmful	JJ	19	amod
18	side	JJ	19	amod
19	effects	NNS	16	dobj
20	and	CC	15	cc
21	by	IN	15	conj
22	lowering	VBG	21	pcomp
23	rejection	NN	24	nn
24	rates	NNS	22	dobj
25	.	.	3	punct

1	Rejection	NN	6	nsubj
2	has	VBZ	6	aux
3	been	VBN	6	cop
4	the	DT	6	det
5	major	JJ	6	amod
6	obstacle	NN	0	root
7	in	IN	6	prep
8	the	DT	12	det
9	approximately	RB	10	quantmod
10	30,000	CD	12	num
11	organ	NN	12	nn
12	transplants	NNS	7	pobj
13	performed	VBN	12	partmod
14	world-wide	RB	13	advmod
15	each	DT	16	det
16	year	NN	13	tmod
17	.	.	6	punct

1	Researchers	NNS	2	nsubj
2	began	VBD	0	root
3	using	VBG	2	xcomp
4	the	DT	5	det
5	drug	NN	3	dobj
6	in	IN	2	prep
7	February	NNP	6	pobj
8	on	IN	2	prep
9	patients	NNS	8	pobj
10	who	WP	12	nsubj
11	had	VBD	12	aux
12	received	VBN	9	rcmod
13	kidney	NN	20	nn
14	,	,	13	punct
15	liver	NN	13	conj
16	,	,	13	punct
17	heart	NN	13	conj
18	and	CC	13	cc
19	pancreas	NN	13	conj
20	transplants	NNS	12	dobj
21	.	.	2	punct

1	Only	RB	4	quantmod
2	two	CD	4	number
3	of	IN	4	quantmod
4	111	CD	5	num
5	transplants	NNS	8	nsubjpass
6	have	VBP	8	aux
7	been	VBN	8	auxpass
8	rejected	VBN	0	root
9	.	.	8	punct

1	The	DT	2	det
2	drug	NN	9	nsubjpass
3	,	,	2	punct
4	discovered	VBN	2	partmod
5	in	IN	4	prep
6	1984	CD	5	pobj
7	,	,	2	punct
8	is	VBZ	9	auxpass
9	metabolized	VBN	0	root
10	from	IN	9	prep
11	soil	NN	12	nn
12	fungus	NN	10	pobj
13	found	VBN	12	partmod
14	in	IN	13	prep
15	Japan	NNP	14	pobj
16	.	.	9	punct

1	The	DT	3	det
2	Pittsburgh	NNP	3	nn
3	patients	NNS	7	nsubj
4	are	VBP	7	cop
5	the	DT	7	det
6	first	JJ	7	amod
7	humans	NNS	0	root
8	to	TO	10	aux
9	be	VB	10	auxpass
10	given	VBN	7	infmod
11	the	DT	12	det
12	drug	NN	10	dobj
13	,	,	12	punct
14	which	WDT	16	nsubjpass
15	is	VBZ	16	auxpass
16	made	VBN	12	rcmod
17	by	IN	16	prep
18	Fujisawa	NNP	19	nn
19	Pharmaceutical	NNP	20	nn
20	Co	NNP	17	pobj
21	.	.	7	punct

1	``	``	16	punct
2	We	PRP	4	nsubj
3	're	VBP	4	aux
4	shocked	JJ	16	ccomp
5	by	IN	4	prep
6	it	PRP	5	pobj
7	,	,	4	punct
8	because	IN	11	mark
9	it	PRP	11	nsubjpass
10	's	VBZ	11	auxpass
11	worked	VBN	4	dep
12	so	RB	13	advmod
13	fast	RB	11	advmod
14	,	,	16	punct
15	''	''	16	punct
16	said	VBD	0	root
17	Dr.	NNP	20	nn
18	Thomas	NNP	20	nn
19	E.	NNP	20	nn
20	Starzl	NNP	16	nsubj
21	,	,	20	punct
22	director	NN	20	appos
23	of	IN	22	prep
24	the	DT	29	det
25	University	NNP	29	dep
26	of	IN	25	prep
27	Pittsburgh	NNP	26	pobj
28	Transplantation	NNP	29	nn
29	Program	NNP	23	pobj
30	,	,	20	punct
31	at	IN	16	prep
32	a	DT	34	det
33	news	NN	34	nn
34	conference	NN	31	pobj
35	here	RB	16	advmod
36	yesterday	NN	16	dep
37	.	.	16	punct

1	``	``	15	punct
2	We	PRP	3	nsubj
3	consider	VBP	15	ccomp
4	it	PRP	7	nsubj
5	a	DT	7	det
6	life-saving	JJ	7	amod
7	drug	NN	3	xcomp
8	,	,	7	punct
9	like	IN	7	prep
10	one	CD	9	pobj
11	for	IN	10	prep
12	AIDS	NNP	11	pobj
13	,	,	15	punct
14	''	''	15	punct
15	said	VBD	0	root
16	Dr.	NNP	18	nn
17	John	NNP	18	nn
18	Fung	NNP	15	nsubj
19	,	,	18	punct
20	an	DT	21	det
21	immunologist	NN	18	appos
22	at	IN	21	prep
23	the	DT	24	det
24	University	NNP	22	pobj
25	of	IN	24	prep
26	Pittsburgh	NNP	25	pobj
27	.	.	15	punct

1	Researchers	NNS	2	nsubj
2	say	VBP	0	root
3	they	PRP	4	nsubj
4	believe	VBP	2	ccomp
5	FK-506	NNP	10	nsubj
6	is	VBZ	10	cop
7	100	CD	8	number
8	times	NNS	10	dep
9	more	RBR	10	advmod
10	effective	JJ	4	ccomp
11	than	IN	10	prep
12	the	DT	15	det
13	traditional	JJ	15	amod
14	anti-rejection	JJ	15	amod
15	drug	NN	11	pobj
16	,	,	15	punct
17	cyclosporine	NN	15	appos
18	,	,	15	punct
19	made	VBN	15	partmod
20	by	IN	19	prep
21	Swiss	JJ	23	amod
22	pharmaceutical	JJ	23	amod
23	giant	NN	25	nn
24	Sandoz	NNP	25	nn
25	Ltd	NNP	20	pobj
26	.	.	2	punct

1	They	PRP	4	nsubjpass
2	are	VBP	4	auxpass
3	also	RB	4	advmod
4	encouraged	VBN	0	root
5	by	IN	4	prep
6	the	DT	10	det
7	relatively	RB	8	advmod
8	mild	JJ	10	amod
9	side	JJ	10	amod
10	effects	NNS	5	pobj
11	of	IN	10	prep
12	FK-506	NNP	11	pobj
13	,	,	10	punct
14	compared	VBN	10	prep
15	with	IN	14	pcomp
16	cyclosporine	NN	15	pobj
17	,	,	16	punct
18	which	WDT	20	nsubj
19	can	MD	20	aux
20	cause	VB	16	rcmod
21	renal	JJ	22	amod
22	failure	NN	20	dobj
23	,	,	22	punct
24	morbidity	NN	22	conj
25	,	,	22	punct
26	nausea	NN	22	conj
27	and	CC	22	cc
28	other	JJ	29	amod
29	problems	NNS	22	conj
30	.	.	4	punct

1	``	``	22	punct
2	The	DT	4	det
3	side	JJ	4	amod
4	effects	NNS	10	nsubj
5	-LCB-	-LRB-	6	punct
6	of	IN	4	dep
7	cyclosporine	NN	6	pobj
8	-RCB-	-RRB-	6	punct
9	have	VBP	10	aux
10	made	VBN	22	ccomp
11	the	DT	12	det
12	penalty	NN	17	nsubj
13	for	IN	12	prep
14	its	PRP$	15	poss
15	success	NN	13	pobj
16	rather	RB	17	advmod
17	high	JJ	10	xcomp
18	,	,	22	punct
19	''	''	22	punct
20	Dr.	NNP	21	nn
21	Starzl	NNP	22	nsubj
22	said	VBD	0	root
23	.	.	22	punct

1	Dr.	NNP	2	nn
2	Fung	NNP	3	nsubj
3	said	VBD	0	root
4	that	IN	9	complm
5	FK-506	NNP	9	nsubj
6	would	MD	9	aux
7	not	RB	9	neg
8	be	VB	9	cop
9	available	JJ	3	ccomp
10	in	IN	9	prep
11	the	DT	12	det
12	market	NN	10	pobj
13	for	IN	9	prep
14	at	IN	16	quantmod
15	least	JJS	14	mwe
16	a	DT	17	num
17	year	NN	13	pobj
18	,	,	9	punct
19	and	CC	9	cc
20	that	IN	26	complm
21	the	DT	24	det
22	FDA	NNP	23	nn
23	approval	NN	24	nn
24	process	NN	26	nsubj
25	usually	RB	26	advmod
26	takes	VBZ	9	conj
27	three	CD	28	num
28	years	NNS	26	dobj
29	to	TO	28	dep
30	five	CD	31	num
31	years	NNS	28	dep
32	.	.	3	punct

1	There	EX	2	expl
2	are	VBP	0	root
3	no	DT	5	det
4	firm	JJ	5	amod
5	plans	NNS	2	nsubj
6	to	TO	7	aux
7	expand	VB	5	infmod
8	the	DT	10	det
9	experimental	JJ	10	amod
10	program	NN	7	dobj
11	beyond	IN	7	prep
12	the	DT	13	det
13	University	NNP	11	pobj
14	of	IN	13	prep
15	Pittsburgh	NNP	14	pobj
16	,	,	13	punct
17	whose	WP$	18	poss
18	hospital	NN	19	nsubj
19	performs	VBZ	13	rcmod
20	the	DT	22	det
21	most	JJS	22	amod
22	transplants	NNS	19	dobj
23	in	IN	22	prep
24	the	DT	25	det
25	world	NN	23	pobj
26	.	.	2	punct

1	Researchers	NNS	4	nsubj
2	could	MD	4	aux
3	n't	RB	4	neg
4	estimate	VB	0	root
5	the	DT	6	det
6	cost	NN	4	dobj
7	of	IN	6	prep
8	the	DT	9	det
9	drug	NN	7	pobj
10	when	WRB	12	advmod
11	it	PRP	12	nsubj
12	reaches	VBZ	6	dep
13	the	DT	14	det
14	market	NN	12	dobj
15	,	,	4	punct
16	but	CC	4	cc
17	they	PRP	18	nsubj
18	said	VBD	4	conj
19	FK-506	NNP	21	nsubj
20	will	MD	21	aux
21	enable	VB	18	ccomp
22	patients	NNS	24	nsubj
23	to	TO	24	aux
24	cut	VB	21	xcomp
25	hospital	NN	26	nn
26	stays	NNS	24	dobj
27	by	IN	24	prep
28	50	CD	29	num
29	%	NN	27	pobj
30	and	CC	21	cc
31	reduce	VB	21	conj
32	the	DT	33	det
33	number	NN	31	dobj
34	of	IN	33	prep
35	blood	NN	36	nn
36	tests	NNS	34	pobj
37	used	VBN	36	partmod
38	to	TO	39	aux
39	monitor	VB	37	xcomp
40	the	DT	41	det
41	dosage	NN	39	dobj
42	of	IN	41	prep
43	cyclosporine	JJ	42	pobj
44	and	CC	43	cc
45	other	JJ	46	amod
46	drugs	NNS	43	conj
47	among	IN	37	prep
48	transplant	NN	49	nn
49	recipients	NNS	47	pobj
50	.	.	4	punct

1	Dr.	NNP	2	nn
2	Starzl	NNP	3	nsubj
3	said	VBD	0	root
4	the	DT	5	det
5	research	NN	9	nsubjpass
6	has	VBZ	9	aux
7	been	VBN	9	auxpass
8	largely	RB	9	advmod
9	financed	VBN	3	ccomp
10	by	IN	9	prep
11	the	DT	13	det
12	National	NNP	13	nn
13	Institute	NNP	10	pobj
14	of	IN	13	prep
15	Health	NNP	14	pobj
16	and	CC	10	cc
17	by	IN	10	conj
18	university	NN	19	nn
19	funds	NNS	17	pobj
20	,	,	9	punct
21	and	CC	9	cc
22	that	IN	26	complm
23	Fujisawa	NNP	26	nsubj
24	did	VBD	26	aux
25	n't	RB	26	neg
26	give	VB	9	conj
27	the	DT	28	det
28	hospital	NN	26	iobj
29	any	DT	30	det
30	grants	NNS	26	dobj
31	.	.	3	punct

1	He	PRP	2	nsubj
2	said	VBD	0	root
3	that	IN	7	complm
4	the	DT	6	det
5	research	NN	6	nn
6	team	NN	7	nsubj
7	had	VBD	2	ccomp
8	no	DT	10	det
9	financial	JJ	10	amod
10	stake	NN	7	dobj
11	in	IN	10	prep
12	the	DT	13	det
13	drug	NN	11	pobj
14	.	.	2	punct

1	``	``	33	punct
2	We	PRP	4	nsubj
3	've	VBP	4	aux
4	known	VBN	33	ccomp
5	for	IN	4	prep
6	six	CD	7	num
7	months	NNS	5	pobj
8	the	DT	9	det
9	effect	NN	4	dobj
10	of	IN	9	prep
11	this	DT	12	det
12	drug	NN	10	pobj
13	,	,	4	punct
14	and	CC	4	cc
15	our	PRP$	16	poss
16	advice	NN	21	nsubj
17	to	TO	16	prep
18	our	PRP$	19	poss
19	people	NNS	17	pobj
20	has	VBZ	21	aux
21	been	VBN	4	conj
22	not	RB	24	neg
23	to	TO	24	aux
24	buy	VB	21	xcomp
25	the	DT	26	det
26	company	NN	28	poss
27	's	POS	26	possessive
28	stock	NN	24	dobj
29	,	,	33	punct
30	''	''	33	punct
31	Dr.	NNP	32	nn
32	Starzl	NNP	33	nsubj
33	said	VBD	0	root
34	,	,	33	punct
35	adding	VBG	33	xcomp
36	that	IN	43	complm
37	profiting	VBG	43	csubj
38	from	IN	37	prep
39	FK-506	NNP	38	pobj
40	would	MD	43	aux
41	n't	RB	43	neg
42	be	VB	43	cop
43	ethical	JJ	35	ccomp
44	.	.	33	punct


